Systemic regulation of adipose metabolism

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 3, 2014, Pages 424-430

  Carmean, Christopher M ^a   Cohen, Ronald N ^a   Brady, Matthew J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Adipocyte; Lipolysis; Pituitary

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CATECHOLAMINE; G PROTEIN COUPLED RECEPTOR; GHRELIN; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR RECEPTOR; HORMONE SENSITIVE LIPASE; HUMAN GROWTH HORMONE; LEPTIN; LEVOTHYROXINE; LIOTHYRONINE; LIPOPROTEIN LIPASE; PROTIRELIN; SOMATOSTATIN; STAT5 PROTEIN; THYROID HORMONE; THYROTROPIN;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; CALORIC RESTRICTION; CELL FUNCTION; CYTOKINE RELEASE; DIET THERAPY; HORMONAL THERAPY; HORMONE RECEPTOR INTERACTION; HORMONE RELEASE; HUMAN; HYPOPHYSIS; INSULIN SENSITIVITY; LIPID STORAGE; LIPOGENESIS; LIPOLYSIS; METABOLIC REGULATION; METABOLIC SYNDROME X; MONOTHERAPY; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; THYROID GLAND; TISSUE METABOLISM;

ADIPOCYTE; LIPOLYSIS; PITUITARY;

ADIPOCYTES; ADIPOSE TISSUE, WHITE; ENDOCRINE SYSTEM; ENERGY METABOLISM; GROWTH HORMONE; HUMANS; LIPID METABOLISM; LIPOLYSIS; PITUITARY GLAND; THYROID HORMONES;

EID: 84893682134     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.06.004     Document Type: Review

References (114)

1. Bianco A.C. Minireview: cracking the metabolic code for thyroid hormone signaling. Endocrinology 2011, 152:3306-3311.
2. Brent G.A. Mechanisms of thyroid hormone action. J. Clin. Invest. 2012, 122:3035-3043.
3. Kaneshige M., Kaneshige K., Zhu X., Dace A., Garrett L., Carter T.A., Kazlauskaite R., Pankratz D.G., Wynshaw-Boris A., Refetoff S., Weintraub B., Willingham M.C., Barlow C., Cheng S. Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:13209-13214.
4. Pearce E.N. Thyroid hormone and obesity. Curr. Opin. Endocrinol. Diabetes Obes. 2012, 19:408-413.
5. Kim B. Thyroid hormone as a determinant of energy expenditure and the basal metabolic rate. Thyroid 2008, 18:141-144.
6. Ribeiro M.O., Bianco S.D., Kaneshige M., Schultz J.J., Cheng S.Y., Bianco A.C., Brent G.A. Expression of uncoupling protein 1 in mouse brown adipose tissue is thyroid hormone receptor-beta isoform specific and required for adaptive thermogenesis. Endocrinology 2010, 151:432-440.
7. Rosen E.D., MacDougald O.A. Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol. 2006, 7:885-896.
8. Obregon M.J. Thyroid hormone and adipocyte differentiation. Thyroid 2008, 18:185-195.
9. Garcia B., Obregon M.J. Growth factor regulation of uncoupling protein-1 mRNA expression in brown adipocytes. Am. J. Physiol. Cell Physiol. 2002, 282:C105-C112.
10. Hernandez A., St Germain D.L., Obregon M.J. Transcriptional activation of type III inner ring deiodinase by growth factors in cultured rat brown adipocytes. Endocrinology 1998, 139:634-639.
11. Carmona M.C., Iglesias R., Obregon M.J., Darlington G.J., Villarroya F., Giralt M. Mitochondrial biogenesis and thyroid status maturation in brown fat require CCAAT/enhancer-binding protein alpha. J. Biol. Chem. 2002, 277:21489-21498.
12. Mishra A., Zhu X.G., Ge K., Cheng S.Y. Adipogenesis is differentially impaired by thyroid hormone receptor mutant isoforms. J. Mol. Endocrinol. 2010, 44:247-255.
13. Ying H., Araki O., Furuya F., Kato Y., Cheng S.Y. Impaired adipogenesis caused by a mutated thyroid hormone alpha1 receptor. Mol. Cell. Biol. 2007, 27:2359-2371.
14. Lu C., Cheng S.Y. Thyroid hormone receptors regulate adipogenesis and carcinogenesis via crosstalk signaling with peroxisome proliferator-activated receptors. J. Mol. Endocrinol. 2010, 44:143-154.
15. Elks M.L., Manganiello V.C. Effects of thyroid hormone on regulation of lipolysis and adenosine 3',5'-monophosphate metabolism in 3T3-L1 adipocytes. Endocrinology 1985, 117:947-953.
16. Hellstrom L., Wahrenberg H., Reynisdottir S., Arner P. Catecholamine-induced adipocyte lipolysis in human hyperthyroidism. J. Clin. Endocrinol. Metab. 1997, 82:159-166.
17. Silva J.E., Bianco S.D. Thyroid-adrenergic interactions: physiological and clinical implications. Thyroid 2008, 18:157-165.
18. Engfeldt P., Arner P., Bolinder J., Wennlund A., Ostman J. Phosphodiesterase activity in human subcutaneous adipose tissue in hyper- and hypothyroidism. J. Clin. Endocrinol. Metab. 1982, 54:625-629.
19. Miksicek R.J., Towle H.C. Changes in the rates of synthesis and messenger RNA levels of hepatic glucose-6-phosphate and 6-phosphogluconate dehydrogenases following induction by diet or thyroid hormone. J. Biol. Chem. 1982, 257:11829-11835.
20. Freake H.C., Moon Y.K. Hormonal and nutritional regulation of lipogenic enzyme mRNA levels in rat primary white and brown adipocytes. J. Nutr. Sci. Vitaminol. (Tokyo) 2003, 49:40-46.
21. Oppenheimer J.H., Schwartz H.L., Lane J.T., Thompson M.P. Functional relationship of thyroid hormone-induced lipogenesis, lipolysis, and thermogenesis in the rat. J. Clin. Invest. 1991, 87:125-132.
22. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 2004, 89:2548-2556.
23. Ahima R.S., Prabakaran D., Mantzoros C., Qu D., Lowell B., Maratos-Flier E., Flier J.S. Role of leptin in the neuroendocrine response to fasting. Nature 1996, 382:250-252.
24. Iglesias P., Diez J.J. Influence of thyroid dysfunction on serum concentrations of adipocytokines. Cytokine 2007, 40:61-70.
25. Syed M.A., Thompson M.P., Pachucki J., Burmeister L.A. The effect of thyroid hormone on size of fat depots accounts for most of the changes in leptin mRNA and serum levels in the rat. Thyroid 1999, 9:503-512.
26. Legradi G., Emerson C.H., Ahima R.S., Flier J.S., Lechan R.M. Leptin prevents fasting-induced suppression of prothyrotropin-releasing hormone messenger ribonucleic acid in neurons of the hypothalamic paraventricular nucleus. Endocrinology 1997, 138:2569-2576.
27. Lin S.Y., Huang S.C., Sheu W.H. Circulating adiponectin concentrations were related to free thyroxine levels in thyroid cancer patients after thyroid hormone withdrawal. Metabolism 2010, 59:195-199.
28. Arrojo E.D.R., Fonseca T.L., Werneck-de-Castro J.P., Bianco A.C. Role of the type 2 iodothyronine deiodinase (D2) in the control of thyroid hormone signaling. Biochim. Biophys. Acta 2013, 1830:3956-3964.
29. Castillo M., Hall J.A., Correa-Medina M., Ueta C., Kang H.W., Cohen D.E., Bianco A.C. Disruption of thyroid hormone activation in type 2 deiodinase knockout mice causes obesity with glucose intolerance and liver steatosis only at thermoneutrality. Diabetes 2011, 60:1082-1089.
30. Brenta G., Danzi S., Klein I. Potential therapeutic applications of thyroid hormone analogs. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3:632-640.
31. Fuglsang J., Ovesen P. Aspects of placental growth hormone physiology. Growth Horm. IGF Res. 2006, 16:67-85.
32. Newbern D., Freemark M. Placental hormones and the control of maternal metabolism and fetal growth. Curr. Opin. Endocrinol. Diabetes Obes. 2011, 18:409-416.
33. Higgins M., Mc Auliffe F. A review of maternal and fetal growth factors in diabetic pregnancy. Curr. Diabetes Rev. 2010, 6:116-125.
34. Hayakawa M., Shimazaki Y., Tsushima T., Kato Y., Takano K., Chihara K., Shimatsu A., Irie M. Metabolic effects of 20-kilodalton human growth hormone (20K-hGH) for adults with growth hormone deficiency: results of an exploratory uncontrolled multicenter clinical trial of 20K-hGH. J. Clin. Endocrinol. Metab. 2004, 89:1562-1571.
35. Baumann G.P. Growth hormone isoforms. Growth Horm. IGF Res. 2009, 19:333-340.
36. Anderson L.L., Scanes C.G. Nanobiology and physiology of growth hormone secretion. Exp. Biol. Med. (Maywood) 2012, 237:126-142.
37. Veldhuis J.D., Keenan D.M. Secretagogues govern GH secretory-burst waveform and mass in healthy eugonadal and short-term hypogonadal men. Eur. J. Endocrinol. 2008, 159:547-554.
38. Anderson L.L., Jeftinija S., Scanes C.G. Growth hormone secretion: molecular and cellular mechanisms and in vivo approaches. Exp. Biol. Med. (Maywood) 2004, 229:291-302.
39. Hartman M.L., Faria A.C., Vance M.L., Johnson M.L., Thorner M.O., Veldhuis J.D. Temporal structure of in vivo growth hormone secretory events in humans. Am. J. Physiol. 1991, 260:E101-E110.
40. Honda Y., Takahashi K., Takahashi S., Azumi K., Irie M., Sakuma M., Tsushima T., Shizume K. Growth hormone secretion during nocturnal sleep in normal subjects. J. Clin. Endocrinol. Metab. 1969, 29:20-29.
41. Holl R.W., Hartman M.L., Veldhuis J.D., Taylor W.M., Thorner M.O. Thirty-second sampling of plasma growth hormone in man: correlation with sleep stages. J. Clin. Endocrinol. Metab. 1991, 72:854-861.
42. Pietrowsky R., Meyrer R., Kern W., Born J., Fehm H.L. Effects of diurnal sleep on secretion of cortisol, luteinizing hormone, and growth hormone in man. J. Clin. Endocrinol. Metab. 1994, 78:683-687.
43. Van Cauter E., Plat L., Scharf M.B., Leproult R., Cespedes S., L'Hermite-Balériaux M., Copinschi G. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young men. J. Clin. Invest. 1997, 100:745-753.
44. Weibel L., Brandenberger G. Disturbances in hormonal profiles of night workers during their usual sleep and work times. J. Biol. Rhythms 1998, 13:202-208.
45. Weibel L., Follenius M., Spiegel K., Gronfier C., Brandenberger G. Growth hormone secretion in night workers. Chronobiol. Int. 1997, 14:49-60.
46. Born J., Muth S., Fehm H.L. The significance of sleep onset and slow wave sleep for nocturnal release of growth hormone (GH) and cortisol. Psychoneuroendocrinology 1988, 13:233-243.
47. Brandenberger G., Weibel L. The 24-h growth hormone rhythm in men: sleep and circadian influences questioned. J. Sleep Res. 2004, 13:251-255.
48. Spiegel K., Leproult R., Colecchia E.F., L'Hermite-Balériaux M., Nie Z., Copinschi G., Van Cauter E. Adaptation of the 24-h growth hormone profile to a state of sleep debt. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 279:R874-R883.
49. Baumann G. Growth hormone binding protein 2001. J Pediatr Endocrinol Metab 2001, 14:355-375.
50. Bazan J.F. A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor beta-chain. Biochem. Biophys. Res. Commun. 1989, 164:788-795.
51. Kelly P.A., Djiane J., Postel-Vinay M.C., Edery M. The prolactin/growth hormone receptor family. Endocr. Rev. 1991, 12:235-251.
52. Cunningham B.C., Bass S., Fuh G., Wells J.A. Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science 1990, 250:1709-1712.
53. Wei Y., Rhani Z., Goodyer C.G. Characterization of growth hormone receptor messenger ribonucleic acid variants in human adipocytes. J. Clin. Endocrinol. Metab. 2006, 91:1901-1908.
54. Dastot F., Sobrier M.L., Duquesnoy P., Duriez B., Goossens M., Amselem S. Alternatively spliced forms in the cytoplasmic domain of the human growth hormone (GH) receptor regulate its ability to generate a soluble GH-binding protein. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:10723-10728.
55. Moffat J.G., Dao H., Talamantes F. Alternative 5'-untranslated regions of mouse GH receptor/binding protein messenger RNA are derived from sequences adjacent to the major L2 promoter. J. Endocrinol. 2000, 167:145-152.
56. Pekhletsky R.I., Chernov B.K., Rubtsov P.M. Variants of the 5'-untranslated sequence of human growth hormone receptor mRNA. Mol. Cell. Endocrinol. 1992, 90:103-109.
57. Wei Y., Puzhko S., Wabitsch M., Goodyer C.G. Structure and activity of the human growth hormone receptor (hGHR) gene V2 promoter. Mol. Endocrinol. 2009, 23:360-372.
58. Wei Y., Puzhko S., Wabitsch M., Goodyer C.G. Transcriptional regulation of the human growth hormone receptor (hGHR) gene V2 promoter by transcriptional activators and repressor. Mol. Endocrinol. 2009, 23:373-387.
59. Arner P. Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract. Res. Clin. Endocrinol. Metab. 2005, 19:471-482.
60. Baik M., Yu J.H., Hennighausen L. Growth hormone-STAT5 regulation of growth, hepatocellular carcinoma, and liver metabolism. Ann. N. Y. Acad. Sci. 2011, 1229:29-37.
61. White U.A., Coulter A.A., Miles T.K., Stephens J.M. The STAT5A-mediated induction of pyruvate dehydrogenase kinase 4 expression by prolactin or growth hormone in adipocytes. Diabetes 2007, 56:1623-1629.
62. Hogan J.C., Stephens J.M. The regulation of fatty acid synthase by STAT5A. Diabetes 2005, 54:1968-1975.
63. Nielsen C., Gormsen L.C., Jessen N., Pedersen S.B., Møller N., Lund S., Jørgensen J.O. Growth hormone signaling in vivo in human muscle and adipose tissue: impact of insulin, substrate background, and growth hormone receptor blockade. J. Clin. Endocrinol. Metab. 2008, 93:2842-2850.
64. Jørgensen J.O., Jessen N., Pedersen S.B., Vestergaard E., Gormsen L., Lund S.A., Billestrup N. GH receptor signaling in skeletal muscle and adipose tissue in human subjects following exposure to an intravenous GH bolus. Am. J. Physiol. Endocrinol. Metab. 2006, 291:E899-E905.
65. Moller L., Dalman L., Norrelund H., Billestrup N., Frystyk J., Moller N., Jorgensen J.O. Impact of fasting on growth hormone signaling and action in muscle and fat. J. Clin. Endocrinol. Metab. 2009, 94:965-972.
66. Fain J.N., Ihle J.H., Bahouth S.W. Stimulation of lipolysis but not of leptin release by growth hormone is abolished in adipose tissue from Stat5a and b knockout mice. Biochem. Biophys. Res. Commun. 1999, 263:201-205.
67. Story D.J., Stephens J.M. Modulation and lack of cross-talk between signal transducer and activator of transcription 5 and suppressor of cytokine signaling-3 in insulin and growth hormone signaling in 3T3-L1 adipocytes. Obesity (Silver Spring) 2006, 14:1303-1311.
68. Samra J.S., Clark M.L., Humphreys S.M., MacDonald I.A., Bannister P.A., Matthews D.R., Frayn K.N. Suppression of the nocturnal rise in growth hormone reduces subsequent lipolysis in subcutaneous adipose tissue. Eur. J. Clin. Invest. 1999, 29:1045-1052.
69. Richelsen B., Pedersen S.B., Kristensen K., Børglum J.D., Nørrelund H., Christiansen J.S., Jørgensen J.O. Regulation of lipoprotein lipase and hormone-sensitive lipase activity and gene expression in adipose and muscle tissue by growth hormone treatment during weight loss in obese patients. Metabolism 2000, 49:906-911.
70. Johannsson G., Mårin P., Lönn L., Ottosson M., Stenlöf K., Björntorp P., Sjöström L., Bengtsson B.A. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J. Clin. Endocrinol. Metab. 1997, 82:727-734.
71. Ottosson M., Vikman-Adolfsson K., Enerbäck S., Elander A., Björntorp P., Edén S. Growth hormone inhibits lipoprotein lipase activity in human adipose tissue. J. Clin. Endocrinol. Metab. 1995, 80:936-941.
72. Richelsen B., Pedersen S.B., Børglum J.D., Møller-Pedersen T., Jørgensen J., Jørgensen J.O. Growth hormone treatment of obese women for 5 wk: effect on body composition and adipose tissue LPL activity. Am. J. Physiol. 1994, 266:E211-E216.
73. Johansen T., Richelsen B., Hansen H.S., Din N., Malmlöf K. Growth hormone-mediated breakdown of body fat: effects of GH on lipases in adipose tissue and skeletal muscle of old rats fed different diets. Horm. Metab. Res. 2003, 35:243-250.
74. Zhao J.T., Cowley M.J., Lee P., Birzniece V., Kaplan W., Ho K.K. Identification of novel GH-regulated pathway of lipid metabolism in adipose tissue: a gene expression study in hypopituitary men. J. Clin. Endocrinol. Metab. 2011, 96:E1188-E1196.
75. Puri V., Ranjit S., Konda S., Nicoloro S.M., Straubhaar J., Chawla A., Chouinard M., Lin C., Burkart A., Corvera S., Perugini R.A., Czech M.P. Cidea is associated with lipid droplets and insulin sensitivity in humans. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:7833-7838.
76. Kelder B., Berryman D.E., Clark R., Li A., List E.O., Kopchick J.J. CIDE-A gene expression is decreased in white adipose tissue of growth hormone receptor/binding protein gene disrupted mice and with high-fat feeding of normal mice. Growth Horm. IGF Res. 2007, 17:346-351.
77. Nordström E.A., Rydén M., Backlund E.C., Dahlman I., Kaaman M., Blomqvist L., Cannon B., Nedergaard J., Arner P. A human-specific role of cell death-inducing DFFA (DNA fragmentation factor-alpha)-like effector A (CIDEA) in adipocyte lipolysis and obesity. Diabetes 2005, 54:1726-1734.
78. Veldhuis J.D., Iranmanesh A., Ho K.K., Waters M.J., Johnson M.L., Lizarralde G. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J. Clin. Endocrinol. Metab. 1991, 72:51-59.
79. Beauville M., Harant I., Crampes F., Riviere D., Tauber M.T., Tauber J.P., Garrigues M. Effect of long-term rhGH administration in GH-deficient adults on fat cell epinephrine response. Am. J. Physiol. 1992, 263:E467-E472.
80. Ueland T., Fougner S.L., Godang K., Lekva T., Schurgers L.J., Scholz H., Halvorsen B., Schreiner T., Aukrust P., Bollerslev J. Associations between body composition, circulating interleukin-1 receptor antagonist, osteocalcin, and insulin metabolism in active acromegaly. J. Clin. Endocrinol. Metab. 2010, 95:361-368.
81. Miyakawa M., Tsushima T., Murakami H., Isozaki O., Demura H., Tanaka T. Effect of growth hormone (GH) on serum concentrations of leptin: study in patients with acromegaly and GH deficiency. J. Clin. Endocrinol. Metab. 1998, 83:3476-3479.
82. Bengtsson B.A., Brummer R.J., Edén S., Bosaeus I. Body composition in acromegaly. Clin. Endocrinol. (Oxf) 1989, 30:121-130.
83. Kaji H., Sugimoto T., Nakaoka D., Okimura Y., Abe H., Chihara K. Bone metabolism and body composition in Japanese patients with active acromegaly. Clin. Endocrinol. (Oxf) 2001, 55:175-181.
84. Marzullo P., Buckway C., Pratt K.L., Colao A., Guevara-Aguirre J., Rosenfeld R.G. Leptin concentrations in GH deficiency: the effect of GH insensitivity. J. Clin. Endocrinol. Metab. 2002, 87:540-545.
85. Rosenfeld R.G., Rosenbloom A.L., Guevara-Aguirre J. Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr. Rev. 1994, 15:369-390.
86. al-Shoumer K.A., Anyaoku V., Richmond W., Johnston D.G. Elevated leptin concentrations in growth hormone-deficient hypopituitary adults. Clin. Endocrinol. (Oxf) 1997, 47:153-159.
87. Gill M.S., Toogood A.A., Jones J., Clayton P.E., Shalet S.M. Serum leptin response to the acute and chronic administration of growth hormone (GH) to elderly subjects with GH deficiency. J. Clin. Endocrinol. Metab. 1999, 84:1288-1295.
88. Bolanowski M., Milewicz A., Bidzińska B., Jedrzejuk D., Daroszewski J., Mikulski E. Serum leptin levels in acromegaly-a significant role for adipose tissue and fasting insulin/glucose ratio. Med. Sci. Monit. 2002, 8:CR685-CR689.
89. Tan K.C., Tso A.W., Lam K.S. Effect of sandostatin LAR on serum leptin levels in patients with acromegaly. Clin. Endocrinol. (Oxf) 2001, 54:31-35.
90. Damjanović S.S., Petakov M.S., Raicević S., Micić D., Marinković J., Dieguez C., Casanueva F.F., Popović V. Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery. J. Clin. Endocrinol. Metab. 2000, 85:147-154.
91. Schoeller D.A., Cella L.K., Sinha M.K., Caro J.F. Entrainment of the diurnal rhythm of plasma leptin to meal timing. J. Clin. Invest. 1997, 100:1882-1887.
92. Berneis K., Vosmeer S., Keller U. Effects of glucocorticoids and of growth hormone on serum leptin concentrations in man. Eur. J. Endocrinol. 1996, 135:663-665.
93. Iranmanesh A., Lizarralde G., Veldhuis J.D. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J. Clin. Endocrinol. Metab. 1991, 73:1081-1088.
94. Vahl N., Jørgensen J.O., Skjaerbaek C., Veldhuis J.D., Orskov H., Christiansen J.S. Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. Am. J. Physiol. 1997, 272:E1108-E1116.
95. Pijl H., Langendonk J.G., Burggraaf J., Frölich M., Cohen A.F., Veldhuis J.D., Meinders A.E. Altered neuroregulation of GH secretion in viscerally obese premenopausal women. J. Clin. Endocrinol. Metab. 2001, 86:5509-5515.
96. Bonert V.S., Elashoff J.D., Barnett P., Melmed S. Body mass index determines evoked growth hormone (GH) responsiveness in normal healthy male subjects: diagnostic caveat for adult GH deficiency. J. Clin. Endocrinol. Metab. 2004, 89:3397-3401.
97. Makimura H., Stanley T., Mun D., You S.M., Grinspoon S. The effects of central adiposity on growth hormone (GH) response to GH-releasing hormone-arginine stimulation testing in men. J. Clin. Endocrinol. Metab. 2008, 93:4254-4260.
98. Cordido F., Garcia-Buela J., Sangiao-Alvarellos S., Martinez T., Vidal O. The decreased growth hormone response to growth hormone releasing hormone in obesity is associated to cardiometabolic risk factors. Mediators Inflamm. 2010, 2010:434562.
99. Freda P.U., Shen W., Heymsfield S.B., Reyes-Vidal C.M., Geer E.B., Bruce J.N., Gallagher D. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J. Clin. Endocrinol. Metab. 2008, 93:2334-2343.
100. Mekala K.C., Tritos N.A. Effects of recombinant human growth hormone therapy in obesity in adults: a meta analysis. J. Clin. Endocrinol. Metab. 2009, 94:130-137.
101. Tomlinson J.W., Crabtree N., Clark P.M., Holder G., Toogood A.A., Shackleton C.H., Stewart P.M. Low-dose growth hormone inhibits 11 beta-hydroxysteroid dehydrogenase type 1 but has no effect upon fat mass in patients with simple obesity. J. Clin. Endocrinol. Metab. 2003, 88:2113-2118.
102. Orskov L., Schmitz O., Jørgensen J.O., Arnfred J., Abildgaard N., Christiansen J.S., Alberti K.G., Orskov H. Influence of growth hormone on glucose-induced glucose uptake in normal men as assessed by the hyperglycemic clamp technique. J. Clin. Endocrinol. Metab. 1989, 68:276-282.
103. Bredella M.A., Lin E., Brick D.J., Gerweck A.V., Harrington L.M., Torriani M., Thomas B.J., Schoenfeld D.A., Breggia A., Rosen C.J., Hemphill L.C., Wu Z., Rifai N., Utz A.L., Miller K.K. Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial. Eur. J. Endocrinol. 2012, 166:601-611.
104. Franco C., Brandberg J., Lönn L., Andersson B., Bengtsson B.A., Johannsson G. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J. Clin. Endocrinol. Metab. 2005, 90:1466-1474.
105. Skaggs S.R., Crist D.M. Exogenous human growth hormone reduces body fat in obese women. Horm. Res. 1991, 35:19-24.
106. Makimura H., Feldpausch M.N., Rope A.M., Hemphill L.C., Torriani M., Lee H., Grinspoon S.K. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J. Clin. Endocrinol. Metab. 2012, 97:4769-4779.
107. Stanley T.L., Chen C.Y., Branch K.L., Makimura H., Grinspoon S.K. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J. Clin. Endocrinol. Metab. 2011, 96:150-158.
108. Snyder D.K., Clemmons D.R., Underwood L.E. Treatment of obese, diet-restricted subjects with growth hormone for 11weeks: effects on anabolism, lipolysis, and body composition. J. Clin. Endocrinol. Metab. 1988, 67:54-61.
109. Nam S.Y., Kim K.R., Cha B.S., Song Y.D., Lim S.K., Lee H.C., Huh K.B. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients. Int. J. Obes. Relat. Metab. Disord. 2001, 25:1101-1107.
110. Ahn C.W., Kim C.S., Nam J.H., Kim H.J., Nam J.S., Park J.S., Kang E.S., Cha B.S., Lim S.K., Kim K.R., Lee H.C., Huh K.B. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control. Clin. Endocrinol. (Oxf) 2006, 64:444-449.
111. Clemmons D.R., Snyder D.K., Williams R., Underwood L.E. Growth hormone administration conserves lean body mass during dietary restriction in obese subjects. J. Clin. Endocrinol. Metab. 1987, 64:878-883.
112. Albert S.G., Mooradian A.D. Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity. J. Clin. Endocrinol. Metab. 2004, 89:695-701.
113. Snyder D.K., Underwood L.E., Clemmons D.R. Anabolic effects of growth hormone in obese diet-restricted subjects are dose dependent. Am. J. Clin. Nutr. 1990, 52:431-437.
114. Snyder D.K., Clemmons D.R., Underwood L.E. Dietary carbohydrate content determines responsiveness to growth hormone in energy-restricted humans. J. Clin. Endocrinol. Metab. 1989, 69:745-752.